About 13 results found for searched term "USP1-IN-5" (0.194 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41455 | USP1-IN-5 | Deubiquitinase |
| USP1-IN-5 is a USP1 inhibitor (IC50<50 nM). | ||
| M10504 | IU1-47 | Deubiquitinase |
| IU 1-47 | ||
| IU1-47 is a potent and specific USP14 inhibitor with an IC50 of 0.6 μM. | ||
| M10751 | USP7-IN-8 | Deubiquitinase |
| USP7-IN-8 is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in the Ub-Rho110 assay.USP7-IN-8 is inactive against USP47 and USP5.USP7-IN-8 has anticancer effects. | ||
| M13632 | USP7-IN-1 | Deubiquitinase |
| USP7-IN-1 is a selective and reversible inhibitor of ubiquitin-specific protease 7 (USP7), with an IC50 of 77 μM, and can be used for the research of cancer. | ||
| M14485 | BCI | Phosphatase |
| (E)-BCI | ||
| BCI is an allosteric inhibitor of dual specificity phosphatase (DUSP). BCI specifically inhibits DUSP6 and DUSP1 with EC50s of 13.3 and 8.0 μM in cells, respectively. BCI does not inhibit DUSP5. | ||
| M20734 | (E/Z)-BCI | Phosphatase |
| BCI, NSC 150117 | ||
| (E/Z)-BCI (BCI, NSC 150117) is an inhibitor of dual specific phosphatase 1/6 (DUSP1/DUSP6) and mitogen-activated protein kinase with EC50 of 13.3 μM and 8.0 μM for DUSP6 and DUSP1 in cells, respectively. (E)-BCI induces apoptosis via generation of reactive oxygen species (ROS) and activation of intrinsic mitochondrial pathway in H1299 lung cancer cells. | ||
| M24657 | Nanrilkefusp alfa | IL Receptor/Related |
| SO-C101; SOT101 | ||
| Nanrilkefusp alfa (SO-C101; SOT101) is fusion protein, is a selective and potent agonist fusion protein of IL-15 and IL-15Rα sushi+ domain. Nanrilkefusp alfa inhibits tumor by inducing proliferation and activation of memory CD8+ T cells, natural killer (NK) cells, γ/δ T cells and NKT cells. Nanrilkefusp alfa exhibits excellent anti-metastatic activity against melanoma and suppresses tumor growth in various mouse tumor models. | ||
| M24993 | Cinrebafusp alfa | EGFR/HER2 |
| PRS 343 | ||
| Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research. | ||
| M29485 | Tuspetinib | FLT3 |
| HM43239 | ||
| Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells. | ||
| M29497 | IU1-248 | Deubiquitinase |
| IU1-248, a derivative of IU1, is a potent and selective USP14 inhibitor with an IC50 of 0.83 μM. | ||
| M41451 | USP7-IN-12 | Deubiquitinase |
| USP7-IN-12 is a potent and orally active Usp7 inhibitor with an IC50 value of 3.67 nM. | ||
| M41452 | USP1-IN-4 | Deubiquitinase |
| USP1-IN-4 is an effective USP1 inhibitor with an IC50 value of 2.44 nM. | ||
| M41456 | USP1-IN-6 | Deubiquitinase |
| USP1-IN-6 is a USP1 inhibitor (IC50<50 nM). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
